CRP and rheumatoid arthritis: Similarly, a 12-month RCT in Sweden, as reported by Larsson et al. found that improvements in disease activity (primary endpoint; per DAS28-4 [ESR] and DAS28-4 [CRP]) were non-inferior in patients with stable chronic IA (CIA; RA, PsA, undifferentiated arthritis, or undifferentiated spondyloarthritis [SpA]) undergoing biologic therapy who had one of two annual rheumatologist monitoring visits replaced by a nurse-led monitoring visit, versus patients who saw a rheumatologist at both visits [31].